Search results
Dec 28, 2016 · David Hilbert has spent the past 20+ years combining his disciplined approach to science with the business of effective drug development and corporate management. He is currently President and CEO at Arcellx, Inc., a company focused on the development of regulated immune cell therapies for treatment of human disease.
Feb 4, 2022 · Arcellx's management includes CEO Rami Elghandour, Chief Medical Officer Christopher Heery, Chief Commercial Officer Neeraj Teotia and Chief Technical Officer David Hilbert, Ph.D., who founded...
- Kyle Lahucik
Oct 3, 2019 · “The financial and strategic support from our investors allows Arcellx to accelerate development of a robust pipeline of ARC-T + sparX programs for patients in need,” commented David Hilbert, Ph.D., President and Chief Executive Officer of Arcellx.
- CEO at Biobuzz/Workforce Genetics
Jan 26, 2021 · Arcellx’s founder and CEO, David Hilbert, Ph.D., will transition to the new role of Chief Technical Officer. “I’m thrilled to join Arcellx and honored to lead the company as it advances its transformative cancer and autoimmune therapies,” said Rami Elghandour.
David Hilbert. Former VP of Research at HGS. Former Founder, CEO and Chief Technical Officer of Arcellx, Serial Entrepreneur. Current Independent Consultant. Hilbert has spent the past 20+ years combining his disciplined approach to science with the business of effective drug development and corporate management.
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies. Gaithersburg, Maryland, United States. 101-250. Post-IPO Equity.
American Gene Technologies (AGT) Overview. AGT is a private biotechnology company pursuing cures and treatments for Infectious diseases, cancers and monogenic disorders. In August 2020, AGT received IND approval to begin Phase 1, the first human clinical trial for their lead HIV program.
